Theranos Investor Riley Bechtel Steps Down From Board -- Update
December 01 2016 - 9:58PM
Dow Jones News
By Christopher Weaver and Ezequiel Minaya
Theranos Inc. said Riley Bechtel, chairman of the construction
giant Bechtel Corp., had retired as a director of the embattled
blood testing startup.
Mr. Bechtel has been replaced by Daniel Warmenhoven, former
chief executive officer of data-storage firm NetApp Inc. The
company said Mr. Bechtel "has health issues," and that the switch
was effective immediately.
Mr. Bechtel was named as an investor in Theranos in a Wall
Street Journal article earlier this week. The article identified
other wealthy individuals and families that led Theranos's most
recent funding round, including Rupert Murdoch, executive chairman
of Wall Street Journal parent News Corp.
Theranos founder Elizabeth Holmes said in a statement that the
firm is "proud to call [Mr. Bechtel] a shareholder and will miss
him on our board."
Theranos said Mr. Bechtel had joined its board in 2014. Mr.
Warmenhoven is also a board member at the closely held Bechtel
Corp.
In a statement issued by Theranos, Mr. Warmenhoven said,
"Theranos' inventions position it to meaningfully contribute to
accessible, affordable health care across a broad range of
settings."
"I have confidence in the company's return to its technology
roots, and I look forward to helping guide it to success," he
said.
The company faces serious challenges. Federal health regulators
sanctioned it in July, barring Ms. Holmes from the lab industry for
at least two years. It faces lawsuits by investors and patients and
civil and criminal federal probes.
The company is appealing the sanctions. It has said the suits
are without merit and that it is cooperating in the
investigations.
In October, it closed it lab testing operations. Ms. Holmes said
at the time the company would focus on developing new lab devices
to sell commercially that would enable cheaper blood tests to be
done on small samples.
On Thursday, the company also announced that it was retiring its
board of counselors structure as part of "an ongoing evolution and
consolidation of the company's corporate advisory framework." The
move is effective Jan. 1. A call seeking further detail wasn't
immediately returned.
Members of the scrapped counselors group were once part of the
board of directors but were shifted to the newly created body in
2015 after critics said that while influential former government
officials, they offered little in expertise in the sector.
The advisers included former U.S. cabinet members Henry A.
Kissinger and George P. Shultz, as well as former U.S.
senators.
It was the grandson of Mr. Shultz, a former secretary of state,
who was the first of Theranos' employees to raise concerns with
state regulators of the company's lab practices.
Write to Christopher Weaver at christopher.weaver@wsj.com and
Ezequiel Minaya at ezequiel.minaya@wsj.com
(END) Dow Jones Newswires
December 01, 2016 21:43 ET (02:43 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
NetApp (NASDAQ:NTAP)
Historical Stock Chart
From Dec 2024 to Jan 2025
NetApp (NASDAQ:NTAP)
Historical Stock Chart
From Jan 2024 to Jan 2025